| DC Field | Value | Language |
|---|
| dc.contributor.author | Tarasova, A. P. | - |
| dc.contributor.author | Danilenko, L. M. | - |
| dc.contributor.author | Tatarenkova, I. A. | - |
| dc.contributor.author | Khavansky, A. V. | - |
| dc.contributor.author | Timokhina, A. S. | - |
| dc.date.accessioned | 2022-05-02T15:35:01Z | - |
| dc.date.available | 2022-05-02T15:35:01Z | - |
| dc.date.issued | 2017 | - |
| dc.identifier.citation | Evaluation of cardioprotective effects of the incritinmimetics exenatideand vildagliptin in the experiment / A.P. Tarasova [et al.] // Research result: pharmacology and clinical pharmacology. - 2017. - Vol. 3, № 2.- P. 57-63. - Doi: 10.18413/2313-8971-2017-3-2-57-63. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46548 | - |
| dc.description.abstract | The results of experimental and clinical trials make it clear that incretin mimetics possess pleiotropic effects and demonstrate the value in terms of assessment of their potential opportunities as cardioprotectors. Goals: To study the cardioprotective effects of exenatide and vildagliptin on the model of doxorubicin-induced cardiomyopathy | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | biology | ru |
| dc.subject | animal physiology | ru |
| dc.subject | incritinomimetics | ru |
| dc.subject | exenatide | ru |
| dc.subject | vildagliptin | ru |
| dc.subject | doxorubicin-induced cardiomyopathy | ru |
| dc.subject | isolated rat heart | ru |
| dc.subject | cardioprotective effects | ru |
| dc.subject | experimental investigations | ru |
| dc.title | Evaluation of cardioprotective effects of the incritinmimetics exenatideand vildagliptin in the experiment | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 3, № 2
|
